Ipratropium class
Pro Research Analysisby 
Searched over 200M research papers for "ipratropium class"
Ipratropium Bromide: Class and Clinical Applications
Introduction to Ipratropium Bromide
Ipratropium bromide is a bronchodilator medication primarily used in the management of chronic obstructive pulmonary disease (COPD) and asthma. It belongs to the class of anticholinergic agents, which work by blocking the action of acetylcholine on muscarinic receptors in the airways, leading to bronchodilation and reduced mucus secretion2 4.
Mechanism of Action: Anticholinergic Pathway
Ipratropium bromide exerts its effects through an anticholinergic pathway. By inhibiting the action of acetylcholine, it decreases cyclic guanosine monophosphate (cGMP) levels, resulting in bronchodilation. This mechanism is particularly effective in conditions like asthma and chronic bronchitis, where airway constriction is a significant problem2.
Efficacy in COPD Management
Comparative Studies with Other Bronchodilators
Several studies have compared the efficacy of ipratropium bromide with other bronchodilators. For instance, a study comparing tiotropium and ipratropium in COPD patients found that tiotropium was significantly more effective in improving lung function over a 13-week period1. However, ipratropium still showed considerable efficacy in improving forced expiratory volume in one second (FEV1) and forced vital capacity (FVC)1.
Long-Term Efficacy and Safety
In a 90-day multi-center study, ipratropium bromide demonstrated superior long-term efficacy compared to metaproterenol, another bronchodilator. Patients treated with ipratropium showed higher peak responses in FEV1 and FVC, with fewer side effects such as tremors, which are common with beta-agonists4.
Role in Acute Asthma Exacerbations
Combination Therapy with Beta-Agonists
Meta-analyses have shown that adding ipratropium to beta-agonist therapy in acute asthma exacerbations provides a modest but statistically significant improvement in pulmonary function. This combination therapy also reduces hospital admission rates, making it a valuable addition to emergency asthma management3 6.
Sequential vs. Simultaneous Administration
Studies have explored the optimal administration sequence of ipratropium and beta-agonists. One study found no significant difference in peak flow improvement whether ipratropium was administered before or after salbutamol, suggesting that simultaneous administration is as effective as sequential administration10.
Other Clinical Applications
Treatment of Clozapine-Induced Hypersalivation
Ipratropium has also been investigated for off-label uses, such as treating clozapine-induced hypersalivation (CIH). However, a randomized, double-blind, placebo-controlled crossover study found no significant reduction in CIH with ipratropium compared to placebo, indicating limited efficacy in this application5.
Management of Vasomotor Rhinitis
In patients with vasomotor rhinitis, ipratropium nasal spray significantly reduced nasal hypersecretion, although it had no effect on nasal blockage, sneezing, or tickling. Despite some mild side effects, a majority of patients found it worth using for severe rhinorrhea9.
Conclusion
Ipratropium bromide is a versatile anticholinergic bronchodilator with proven efficacy in managing COPD and acute asthma exacerbations. While it shows significant benefits in pulmonary function and reducing hospital admissions when used in combination with beta-agonists, its effectiveness in other conditions like clozapine-induced hypersalivation is less clear. Overall, ipratropium remains a critical component in the therapeutic arsenal for obstructive pulmonary diseases.
Sources and full results
Most relevant research papers on this topic
A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease
Tiotropium significantly improves lung function and peak expiratory flow more effectively than ipratropium in chronic obstructive pulmonary disease patients.
RCT
Highly CitedBronchodilator action of the anticholinergic drug, ipratropium bromide (Sch 1000), as an aerosol in chronic bronchitis and asthma.
Ipratropium bromide is an effective bronchodilator for both asthma and chronic bronchitis, with optimal doses of 40 to 80 mcg, and shows prolonged efficacy compared to isoproterenol.
RCTHighly CitedThe role of ipratropium bromide in the emergency management of acute asthma exacerbation: a metaanalysis of randomized clinical trials.
Ipratropium bromide combined with beta-agonists effectively improves airflow and reduces hospitalizations in adults with acute asthma exacerbation.
Meta-AnalysisHighly CitedComparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study.
Inhaled ipratropium bromide is more effective and safer than metaproterenol for long-term treatment of chronic obstructive pulmonary disease (COPD).
RCTHighly CitedTreatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study.
Ipratropium bromide failed to demonstrate significant clinical effect in treating clozapine-induced hypersalivation compared to placebo in a randomized, double-blind, placebo-controlled trial.
RCTA meta-analysis of the effects of ipratropium bromide in adults with acute asthma.
Ipratropium bromide adds modest improvement in pulmonary function and reduces hospital admissions in adults with acute asthma treated with beta-agonists.
Meta-AnalysisHighly CitedSevere exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy.
Ipratropium is not necessary for initial emergency treatment of COPD or asthma, and can be safely discontinued after 24 hours to reduce costs and complexity.
RCTComparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study.
Ipratropium bromide has longer duration of action and may be effective when beta 2 agonists are not effective in treating chronic obstructive pulmonary disease.
RCTIntranasal ipratropium in the treatment of vasomotor rhinitis.
Ipratropium significantly reduces nasal hypersecretion in patients with vasomotor rhinitis, but does not affect nasal blockage, sneezing, or tickling.
RCTNebulized ipratropium in the treatment of acute asthma.
Ipratropium alone or combined with salbutamol does not significantly improve peak flow rates in acute asthma patients.
RCTHighly Cited